米拉Gabalin 与普瑞巴林治疗胰腺癌患者化疗引起的周围神经病变。
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
机构信息
Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.
出版信息
BMC Cancer. 2021 Dec 9;21(1):1319. doi: 10.1186/s12885-021-09069-9.
BACKGROUND
The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of these two regimens. The efficacy of pregabalin for CIPN has been reported in previous studies. However, the efficacy of mirogabalin for CIPN remains unknown. Thus, in this study, we aimed to clarify which drug (mirogabalin or pregabalin) was more valuable for improving CIPN.
METHODS
A total of 163 PC patients who underwent FOLFIRINOX or GnP between May 2014 and January 2021 were enrolled. Among them, 34 patients were diagnosed with CIPN. Thirteen patients were treated with mirogabalin (mirogabalin group), and twenty-one patients were treated with pregabalin (pregabalin group). Treatment efficacy was compared between the two groups.
RESULTS
In both the mirogabalin group and the pregabalin group, the grade of patients with CIPN at 2, 4, and 6 weeks after the initiation of treatment showed significant improvement compared to the pretreatment grade. Notably, the rate of CIPN improvement was higher in the mirogabalin group than in the pregabalin group (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 6 weeks: 92.3% (12/13) vs 33.3% (7/21), P value = 0.001).
CONCLUSIONS
Although both mirogabalin and pregabalin were effective at improving CIPN, mirogabalin might be a suitable first choice for CIPN in PC patients.
TRIAL REGISTRATION
Not applicable.
背景
新的化疗方案（5-氟尿嘧啶、奥沙利铂、伊立替康和亚叶酸（FOLFIRINOX）或吉西他滨联合白蛋白紫杉醇（GnP））改善了胰腺癌（PC）的预后。不幸的是，这两种方案均会引起化疗引起的周围神经病变（CIPN），这是一种常见的不良反应。先前的研究已经报道了普瑞巴林治疗 CIPN 的疗效。然而，米罗加巴林治疗 CIPN 的疗效尚不清楚。因此，在这项研究中，我们旨在阐明哪种药物（米罗加巴林或普瑞巴林）更能改善 CIPN。
方法
共纳入 2014 年 5 月至 2021 年 1 月期间接受 FOLFIRINOX 或 GnP 治疗的 163 例 PC 患者。其中，34 例患者被诊断为 CIPN。13 例患者接受米罗加巴林（米罗加巴林组）治疗，21 例患者接受普瑞巴林（普瑞巴林组）治疗。比较两组的治疗效果。
结果
在米罗加巴林组和普瑞巴林组中，治疗开始后 2、4 和 6 周时 CIPN 患者的分级均较治疗前显著改善。值得注意的是，米罗加巴林组 CIPN 改善率高于普瑞巴林组（2 周：84.6%（11/13）比 33.3%（7/21），P 值=0.005；4 周、6 周：92.3%（12/13）比 33.3%（7/21），P 值=0.001）。
结论
虽然米罗加巴林和普瑞巴林均能有效改善 CIPN，但米罗加巴林可能是 PC 患者 CIPN 的首选药物。
试验注册
不适用。
Zotero 插件